Dr. Siegel approves of Medicare coverage for Ozempic
Fox News senior medical analyst Dr. Marc Siegel evaluates the Biden administration’s push to expand weight-loss drug coverage ...
Buy Recommendation for Anavex Life Sciences: Promising Alzheimer’s Treatment and Expanding Clinical Pipeline
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of ...
Pharmabiz7h
Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...
He's a doctor studying why lung cancer rates are rising in Asian Americans with no smoking history. Now he's also a patient.
Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
MM&M11h
Rx Rundown: Roche, Sarepta Therapeutics, Merck and more
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
BioSpace15h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...